Document Detail


Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid.
MedLine Citation:
PMID:  12063087     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aliphatic alcohol 1,4-butanediol in converted into gamma-hydroxybutyric acid (GHB) via two enzymatic steps: first, it is oxidised by alcohol dehydrogenase in gamma-hydroxybutyraldehyde; second, the latter is transformed, likely by aldehyde dehydrogenase, into GHB. Initially, the present study compared the sedative/hypnotic effect of GHB and 1,4-butanediol, measured as loss of righting reflex. 1,4-Butanediol was more potent than GHB, presumably because of a more rapid penetration of the blood brain barrier. Further alcohol dehydrogenase inhibitors, 4-methylpyrazole and ethanol, totally prevented the sedative/hypnotic effect of 1,4-butanediol; the aldehyde dehydrogenase inhibitor disulfiram partially blocked the sedative/hypnotic effect of 1,4-butanediol. Finally, the sedative/hypnotic effect of 1,4-butanediol was antagonised by the GABA(B) receptor antagonists, SCH 50911 [(2S)(+)-5,5-dimethyl-2-morpholineacetic acid] and CGP 46381 [(3-aminopropyl)(cyclohexylmethyl)phosphinic acid], but not by the putative GHB receptor antagonist NCS-382 (6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohept-6-ylideneacetic acid), indicating that it is mediated by GABA(B) but not GHB receptors. Taken together, these results suggest that the sedative/hypnotic effect of 1,4-butanediol is mediated by its conversion in vivo into GHB which, in turn, binds to GABA(B) receptors. Accordingly 1,4-butanediol, unlike GHB, failed to displace [(3)H]GHB and [(3)H]baclofen in brain membranes.
Authors:
Mauro A M Carai; Giancarlo Colombo; Roberta Reali; Salvatore Serra; Ignazia Mocci; M Paola Castelli; Giorgio Cignarella; Gian Luigi Gessa
Related Documents :
2032927 - Clinical evaluation of gamma-vinyl-gamma-aminobutyric acid for control of epilepsy in d...
11553667 - Gamma-hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and...
20399837 - Changes of some amino acid concentrations in the medial vestibular nucleus of conscious...
21163157 - Alkaptonuria.
18344607 - Mouse organic anion transporter 2 (moat2) mediates the transport of short chain fatty a...
11228967 - Enhanced biodegradation of petrochemical wastewater using ozonation and bac advanced tr...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of pharmacology     Volume:  441     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2002 Apr 
Date Detail:
Created Date:  2002-06-13     Completed Date:  2002-12-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  157-63     Citation Subset:  IM    
Affiliation:
Neuroscienze S.c.a r.l., Via Palabanda 9, I-09123 Cagliari, Italy. mauro.carai@ns.crs4.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Butylene Glycols / metabolism*,  pharmacology*
Cerebral Cortex / metabolism
Dose-Response Relationship, Drug
Enzyme Inhibitors / pharmacology
Ethanol / pharmacology
Hydroxybutyrates / metabolism*,  pharmacology*
Male
Mice
Mice, Inbred DBA
Rats
Rats, Sprague-Dawley
Receptors, GABA-B / metabolism*
Sleep / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Butylene Glycols; 0/Enzyme Inhibitors; 0/Hydroxybutyrates; 0/Receptors, GABA-B; 110-63-4/1,4-butanediol; 591-81-1/4-hydroxybutyric acid; 64-17-5/Ethanol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of chronic treatment with the protein kinase C inhibitor staurosporine on the acquisition and...
Next Document:  Preconditioning of rat hearts by adenosine A1 or A3 receptor activation.